After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Roivant Sciences Ltd. (ROIV) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $8.17. The Roivant Sciences Ltd. has recorded 40,686 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $8.17 and fluctuated between $8.29 as its day high and $7.82 as its day low. The current market capitalization of Roivant Sciences Ltd. is $6.04B. A total of 1.16 million shares were traded on the day, compared to an average of 2.53M shares.
In the most recent transaction, Pulik Richard sold 1,912 shares of ROIV for 8.08 per share on Mar 01. After the transaction, the CFO now owns 223,347 company shares. In a previous transaction on Feb 22, Ramaswamy Vivek sold 4,000,000 shares at 7.95 per share. ROIV shares that Director owns now total 54,409,211.
Among the insiders who sold shares, Venker Eric disposed of 24,037 shares on Jan 05 at a per-share price of $8.02. This resulted in the President & COO holding 729,429 shares of ROIV after the transaction. In another insider transaction, Venker Eric sold 95,484 shares at $7.32 per share on Jan 03. Company shares held by the President & COO now total 753,466.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ROIV in the last 3 months, the mean price target is $13.25 with high estimates of $19.00 and low estimates of $10.00. In terms of 52-week highs and lows, ROIV has a high of $10.00 and a low of $2.52.
As of this writing, ROIV has an earnings estimate of -$0.39 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.5. The company reported an EPS of -$0.48 in the last quarter, which was -50.00% lower than expectations of -$0.32.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ROIV is Overweight with a score of 5.00. A total of 9 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
